NEW YORK (GenomeWeb News) – IncellDx and Accuri Cytometers today said that they will combine their respective technologies to offer a cervical cancer screening tool.
Menlo Park, Calif.-based IncellDx's HPV OncoTect E6, E7 mRNA test quantifies overexpression of E6/E7 mRNA in each cell, as well as the total proportion of cells that are overexpressing, the firm said. The test will be performed on Accuri's C6 Flow Cytometer, and according to the firms, will provide a more specific indication on whether an HPV infection is transforming into cervical cancer.
"The robust, bench-top flow cytometer system has demonstrated excellent performance when combined with reagents from the HPV OncoTectTM E6, E7 mRNA Kit," Bruce Patterson, CEO of IncellDx, said in a statement. "With this agreement, IncellDx will have an automated, complete solution for cervical cancer screening with the potential to be widely disseminated in the global market."
The test can be performed on routine liquid-based cytology samples and provides results in around 3.5 hours, IncellDx said. The HPV OncoTect is CE marked and is sold in Europe, South America, and Southeast Asia. However, neither the C6 Flow Cytometer nor the test are cleared by the US Food and Drug Administration for marketing in the US.
The firms noted that Accuri's instrument can perform IncellDx's HIVTROPISM Probe and HCVVR Viral Reservoirs Prove, both of which are sold as Research Use Only products.